The evolution of ICER’s review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER’s reports

BACKGROUND: Since its inception in 2006, the Institute for Clinical and Economic Review (ICER) has rapidly gained influence on drug pricing and reimbursement decisions despite historical resistance to the use of cost-effectiveness thresholds in the US health care system. Although patient groups, phy...

Descripción completa

Detalles Bibliográficos
Autores principales: Ronquest, Naoko A, Paret, Kyle, Gould, Ian Gopal, Barnett, Christine L, Mladsi, Deirdre M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390909/
https://www.ncbi.nlm.nih.gov/pubmed/34714108
http://dx.doi.org/10.18553/jmcp.2021.27.11.1601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390909/
https://www.ncbi.nlm.nih.gov/pubmed/34714108
http://dx.doi.org/10.18553/jmcp.2021.27.11.1601

Ejemplares similares